129 related articles for article (PubMed ID: 30649375)
1. Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults.
Wasmann RE; Smit C; Ter Heine R; Koele SE; van Dongen EPH; Wiezer RMJ; Burger DM; Knibbe CAJ; Brüggemann RJM
J Antimicrob Chemother; 2019 Apr; 74(4):978-985. PubMed ID: 30649375
[TBL] [Abstract][Full Text] [Related]
2. Assessment of micafungin loading dosage regimens against Candida spp. in ICU patients by Monte Carlo simulations.
Lu X; Xu G; Chen L; Fan J; Li M; Zhu L
Eur J Clin Pharmacol; 2020 May; 76(5):695-702. PubMed ID: 32047965
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.
Martial LC; Ter Heine R; Schouten JA; Hunfeld NG; van Leeuwen HJ; Verweij PE; de Lange DW; Pickkers P; Brüggemann RJ
Clin Pharmacokinet; 2017 Oct; 56(10):1197-1206. PubMed ID: 28144840
[TBL] [Abstract][Full Text] [Related]
5. Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study.
Chandra S; Fukuda T; Mizuno K; Davies SM; Teusink-Cross A; Tarin R; Marsh RA; Vinks AA; Mehta PA
J Antimicrob Chemother; 2018 Jun; 73(6):1651-1658. PubMed ID: 29481593
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of micafungin over repeated doses in critically ill patients: a need for a loading dose?
Kapralos I; Mainas E; Neroutsos E; Apostolidi S; Siopi M; Apostolopoulou O; Dimopoulos G; Sambatakou H; Valsami G; Meletiadis J; Dokoumetzidis A
J Pharm Pharmacol; 2020 Dec; 72(12):1750-1760. PubMed ID: 32789881
[TBL] [Abstract][Full Text] [Related]
7. Optimization of Micafungin Dosage for Chinese Patients with Sepsis in the Intensive Care Unit Based on a Population Pharmacokinetic-Pharmacodynamic Analysis.
Zhong S; Zhu X; Zhao L; Song Y; Yu J; Zheng Z; Zang B
Pharm Res; 2021 Jan; 38(1):67-77. PubMed ID: 33404989
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis.
Muilwijk EW; Maertens JA; van der Velden WJFM; Ter Heine R; Colbers A; Burger DM; Andes D; Theunissen K; Blijlevens NMA; Brüggemann RJM
J Antimicrob Chemother; 2018 Nov; 73(11):3095-3101. PubMed ID: 30137340
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
Boonstra JM; van der Elst KC; Veringa A; Jongedijk EM; Brüggemann RJ; Koster RA; Kampinga GA; Kosterink JG; van der Werf TS; Zijlstra JG; Touw DJ; Alffenaar JWC
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971861
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.
Jullien V; Azoulay E; Schwebel C; Le Saux T; Charles PE; Cornet M; Souweine B; Klouche K; Jaber S; Trouillet JL; Bruneel F; Cour M; Cousson J; Meziani F; Gruson D; Paris A; Darmon M; Garrouste-Orgeas M; Navellou JC; Foucrier A; Allaouchiche B; Das V; Gangneux JP; Ruckly S; Wolff M; Timsit JF;
J Antimicrob Chemother; 2017 Jan; 72(1):181-189. PubMed ID: 27609051
[TBL] [Abstract][Full Text] [Related]
11. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.
Xu G; Zhu L; Liao S; Ge T; Yang J
Int J Antimicrob Agents; 2015 Dec; 46(6):631-41. PubMed ID: 26602452
[TBL] [Abstract][Full Text] [Related]
12. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial.
Leroux S; Jacqz-Aigrain E; Elie V; Legrand F; Barin-Le Guellec C; Aurich B; Biran V; Dusang B; Goudjil S; Coopman S; Garcia Sanchez R; Zhao W; Manzoni P;
Br J Clin Pharmacol; 2018 Sep; 84(9):1989-1999. PubMed ID: 29744900
[TBL] [Abstract][Full Text] [Related]
14. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration.
Maseda E; Grau S; Villagran MJ; Hernandez-Gancedo C; Lopez-Tofiño A; Roberts JA; Aguilar L; Luque S; Sevillano D; Gimenez MJ; Gilsanz F
J Antimicrob Chemother; 2014 Jun; 69(6):1624-32. PubMed ID: 24505092
[TBL] [Abstract][Full Text] [Related]
15. Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis.
Grau S; Luque S; Campillo N; Samsó E; Rodríguez U; García-Bernedo CA; Salas E; Sharma R; Hope WW; Roberts JA
J Antimicrob Chemother; 2015 Oct; 70(10):2854-61. PubMed ID: 26180134
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluation of twice-a-week micafungin for prophylaxis of invasive fungal disease in children with acute lymphoblastic leukaemia: a prospective observational cohort study.
Bury D; Wolfs TFW; Ter Heine R; Muilwijk EW; Tissing WJE; Brüggemann RJ
J Antimicrob Chemother; 2022 Feb; 77(3):699-703. PubMed ID: 34939125
[TBL] [Abstract][Full Text] [Related]
18. Prospective Cohort Study of Micafungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-abdominal Infections.
Garbez N; Mbatchi L; Wallis SC; Muller L; Lipman J; Roberts JA; Lefrant JY; Roger C
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0230720. PubMed ID: 33846133
[TBL] [Abstract][Full Text] [Related]
19. Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients.
Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Mejia JL; Roberts MS; Sinnollareddy MG; Roger C; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2016 Nov; 60(11):6550-6557. PubMed ID: 27550344
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of Micafungin in Critically Ill Patients.
Gastine S; Lanckohr C; Blessou M; Horn D; Fobker M; Bause D; Hempel G; Ellger B
Sci Rep; 2019 Nov; 9(1):17741. PubMed ID: 31780687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
